Zymeworks (Canada)

Recent papers from Zymeworks (Canada)

1. Electrochemiluminescence immunoassay for quantifying ZMA001 in human serum: method development, validation, and clinical pharmacokinetic applicationBioanalysis · 2026
2. Antibody-drug conjugates in precision oncologyCancer Cell · 2026
3. Real-world pharmacovigilance analysis for antibody drug conjugates (ADCs) in treatment of solid tumor malignancies.Journal of Clinical Oncology · 2026
4. Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugatesScientific Reports · 2026
5. ZW191, a FRα-targeted topoisomerase 1 inhibitor ADC with a differentiated antitumor efficacy and tolerability profileClinical Cancer Research · 2026
6. Abstract CT306: Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation resultsCancer Research · 2026
7. Abstract 2400: Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads.Cancer Research · 2026
8. Abstract 5640: ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancerCancer Research · 2026
9. Abstract 1686: Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancerCancer Research · 2026
10. Abstract 1642: A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancersCancer Research · 2026
11. Abstract 4542: Zanidatamab modulates multiple pathways involved in tumor growth and survival and is efficacious post T-DXdCancer Research · 2026
12. Abstract 4431: ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancersCancer Research · 2026
13. Abstract 1707: ZW191 - a differentiated FRα-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugsCancer Research · 2026
14. Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In VivoBioconjugate Chemistry · 2026
15. A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).Journal of Clinical Oncology · 2026
16. Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 TrialJTO Clinical and Research Reports · 2025
17. MAiD: How Slippery is its Slope?HEC Forum · 2025
18. The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy– and Radiomics-Based Technologies for Immuno-oncology Biomarker Discovery and ApplicationClinical Cancer Research · 2025
19. The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and ApplicationClinical Cancer Research · 2024
20. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of DevelopmentCancer Discovery · 2024